Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cytokine release syndrome

Cytokine release syndrome

Part of Systemic Inflammatory Response Syndrome

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cytokine release syndrome

5 trials tracked for cytokine release syndrome.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5
  1. Phase 2 A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Completed
  2. Phase 2 A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Completed
  3. Phase 2 Efficacy and Safety of Itolizumab in COVID-19 Complications Completed
  4. Phase 2 Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Completed
  5. Phase 2 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma
Oncology Sys. Review
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma New Proteins May Help Control Inflammation in Multiple Myeloma Treatment
This mini-review explores the roles of IL-37 and IL-38 as potential immunoregulatory checkpoints in patients with relapsed/refractory multip…
Two specific proteins, IL-37 and IL-38, may help control dangerous inflammation during CAR-T cell therapy for multiple myeloma.
Frontiers Aug 23, 2026
CAR T-cell therapy linked to endocrine adverse events in FAERS analysis
Rheumatology Cohort
CAR T-cell therapy linked to endocrine adverse events in FAERS analysis CAR T-cell therapy may trigger rare but serious hormone problems like adrenal failure
A retrospective disproportionality analysis and literature review of 269 endocrine adverse event reports from the FAERS database (2017 to Q2…
CAR T-cell therapy can trigger rare but serious hormone problems like adrenal failure, and death risk rises when these issues occur with sev…
Frontiers Apr 16, 2026